Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Irene Bouchliou"'
Autor:
Evangelia Nakou, Ioannis Kotsianidis, Dimitrios Stakos, Paraskevi Miltiades, Irene Bouchliou, Prodromos Babageorgakas, Emmanouil Spanoudakis, Dimitrios Margaritis, Dimitrios Tziakas
Publikováno v:
Cardiovascular Drugs and Therapy. 26:293-299
To assess the difference in the prevalence of invariant Natural Killer T (iNKT) lymphocytes between hyperlipidemic and control individuals and to evaluate changes in iNKT cell levels after 6 months lipid lowering therapy. A total of 77 hyperlipidemic
Autor:
Ioannis Kotsianidis, Vasilia Garypidou, Aggelos Goutzouvelidis, Sofia Vakalopoulou, Vasiliki Kotoula, Irene Bouchliou, Emmanouil Spanoudakis, George Bourikas, Paraskevi Miltiades, Costas Tsatalas, Evangelia Nakou
Publikováno v:
Clinical Immunology. 139:350-359
Foxp3(+) T regulatory cells (Tregs) and Th17 cells accumulate synchronously at tumor sites during cancer progression, where their interplay is apparently affecting the efficiency of the antitumor response. In myelodysplastic syndromes, a hematopoieti
Autor:
Anastasios Karadimitris, Anna V. Christophoridou, Dimitrios Margaritis, Ioannis Kotsianidis, Athanasios Anastasiades, Christina Tsigalou, Irene Bouchliou, Costas Tsatalas, Georgios Bourikas, E. Spanoudakis, Evangelia Nakou
Publikováno v:
Leukemia. 23:510-518
CD4(+)CD25(+)FOXP3(+) T regulatory cells (T(regs)) prevent autoimmunity by restricting overexuberant immune responses, but the same subpopulation can incur detrimental effects on antitumor responses. In both cases, the suppressor potential of T(regs)
Autor:
Eleytherios Moustakidis, Evangelia Nakou, Emmanouil Spanoudakis, Anastasios Karadimitris, Chrisa M. Vadikolia, Costas Tsatalas, Irene Bouchliou, Richard Szydlo, Paraskevi Miltiades, Ioannis Kotsianidis
Publikováno v:
American journal of clinical pathology. 136(3)
Immunophenotyping is indispensable in the differential diagnosis of B-cell chronic lymphoproliferative disorders (B-CLPDs). However, B-CLPDs often show overlapping immunophenotypic profiles and may be diagnostically challenging. CD1d is an HLA class
Autor:
Anna V. Christophoridou, Athanasios Anastasiades, Evangelia Nakou, Aggelos Goutzouvelidis, Costas Tsatalas, Emmanouil Spanoudakis, Irene Bouchliou, George Bourikas, Ioannis Kotsianidis, Dimitrios Margaritis
Publikováno v:
American Journal of Hematology.
Autor:
Evangelia Nakou, Paschalis Steiropoulos, Irene Bouchliou, Demosthenes Bouros, Ioannis Kotsianidis, Dimitrios Margaritis, Vassilis Aidinis, Emmanouil Spanoudakis, Ioannis Sotiriou, Costas Tsatalas, Argyrios Tzouvelekis
Publikováno v:
American journal of respiratory and critical care medicine. 179(12)
The implication of T cells in the pathogenesis of idiopathic pulmonary fibrosis (IPF) is controversial. CD4(+)CD25(+)FOXP3(+) regulatory T cells (Tregs) are pivotal in maintaining immune homeostasis, but their role in IPF pathophysiology has not yet
Autor:
A. Galanopoulos, Costas Tsatalas, Maria Papaioannou, E. Spanoudakis, Ioannis Kotsianidis, S. Papageorgiou, E. Moustakides, Theodoros P. Vassilakopoulos, Vassiliki Pappa, Sofia Vakalopoulou, Irene Bouchliou, Helen A. Papadaki, Evangelia Nakou, Paraskevi Miltiades
Publikováno v:
Leukemia Research. 35:S123-S124
Autor:
Irene Bouchliou, Evangelia Nakou, A. Goutzouvelidis, Athanasios Anastasiades, Ioannis Kotsianidis, Dimitrios Margaritis, Costas Tsatalas, D. Bouricas
Publikováno v:
Leukemia Research. 31:S67-S68
Autor:
Konstantinos Tsatalas, George Bourikas, Evangelia Nakou, Anastasios Karadimitris, asiliki Kotoula, Richard Szydlo, Irene Bouchliou, E. Spanoudakis, Ioannis Kotsianidis, Paraskevi Miltiades, Dimitrios Margaritis, Eleytherios Moustakidis
Publikováno v:
Blood. 116:3576-3576
Abstract 3576 Immunophenotype holds central role in the differential diagnosis of leukemic B-chronic lymphoproliferative disorders (B-CLPDs). However, select cases show overlapping characteristics and represent a diagnostic challenge. CD1d is an MHC-
Publikováno v:
Clinical Medicine Insights: Therapeutics, Vol 1 (2009)
The illumination of cellular processes in cancer has revolutionized oncology drug development leading to a shift from non-specific chemotherapy to the selective targeting of tumorigenic signal transduction pathways. Farnesyltransferase inhibitors (FT